Merck’s antihypertensive losartan – marketed as a single agent in Cozaar and combined with hydrochlorothiazide in Hyzaar – was the first angiotensin II inhibitor to receive FDA approval. The drug is generally well tolerated and highly effective for treating hypertension, producing a smooth, gradual, 24-hour reduction in blood pressure without significant side effects. Losartan is [...]
Although 14 million Americans are now being treated for hypertension, some estimates indicate that approximately 3 million remain poorly controlled. For some of these, the options for treatment have now expanded with the introduction of Lexxel, a combination antihypertensive agent that consists of an outer layer of enalapril maleate surrounding a core that consists of [...]
